The spatial distribution of esophageal cancer ASMR (A) and ASDR (B) attributable to high BMI in 2019.

Cancer-related pain is one of the common priority symptoms in advanced lung cancer patients at the end-of-life. Alleviating pain is undoubtedly a critical component of palliative care in lung cancer. Through reviewing the urban city medical insurance data of lung cancer patients in China, our study firstly showed that the problem of analgesic undertreatment exists among patients with lung cancer at the end-of-life. Worsening opioid access in the last 30 days of life was explored as a potential cause of undertreated end-of-life pain in lung cancer patients.

Our analysis revealed a series of genes that promote tumor immune function (CCR5, LYZ, IGKC, MS4A1, etc.) and inhibit tumor immune function (SCGB2A2, CD24, etc.).

A total of 431 patients from cBioPortal for Cancer Genomics and 1604 patients from Shanghai Pulmonary Hospital were included in order to investigate the proportion, clinicopathological features, and prognostic significance of patients with stage I LUAD carrying BRAF mutations. Overall, BRAF V600E mutations were detected in six (1.4%) patients in Caucasian populations and 16 (1.0%) patients in Chinese populations. In addition, we demonstrated that BRAF status may not be capable of predicting prognosis in stage I LUAD patients. There is a need for more data to validate our findings.

This figure shows molecular mechanism of adapalene. Adapalene decreased the expression level of AQP3, proinflammatory cytokines such as CCL2 and CCL27. Adapalene upregulated the expression of an antimicrobial peptide, hBD3, and adhesion factors, E-cadherin.

The clinical staging accuracy of NSCLC is higher than before the use of EBUS and PET-CT. Especially, the rate of unforeseen N2, which is important in the treatment plan, is decreased. Increasing the number of skilled bronchoscopy specialists for EBUS screening would be helpful in improving clinical staging accuracy and prognosis of patients with NSCLC.

We developed and validated a radiomics nomogram prediction model for predicting the intracranial efficacy of immune checkpoint inhibitors (ICIs) in small cell lung cancer (SCLC) patients with brain metastases (BMs). This study can help tailor their treatment schedules, improve clinical decision-making, and offer extensive potential applications.

(A) At initial hospitalization. (B) One month after osimertinib readministration.